Chemical Name: 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
Biological ActivityPotent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Citations for Crizotinib
The citations listed below are publications that use Tocris products. Selected citations for Crizotinib include:
4 Citations: Showing 1 - 4
Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents.
Onco Targets Ther 2017;10:4869
Crosstalk between bone marrow-derived myofibroblasts and gastric cancer cells regulates cancer stemness and promotes tumorigenesis.
Authors: Zhu Et al.
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.
Authors: Sullivan Et al.
FASEB J 2012;8:646
Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
Authors: Qi Et al.
Cancer Res 2011;71:1081
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
VersaClone cDNA Plasmids
Reviews for Crizotinib
There are currently no reviews for this product. Be the first to review Crizotinib and earn rewards!
Have you used Crizotinib?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image